Investor FAQs
BioLife Solutions’ common stock is traded on the NASDAQ Global Market under the symbol BLFS.
BioLife Solutions was incorporated in 1987 and is headquartered in Bothell, Washington, USA.
BioLife Solutions develops and supplies biopreservation media, automated cell processing systems, and cryogenic storage solutions that enable cell and gene therapy developers to safely manufacture, store, and deliver advanced therapies. Our tools reduce variability, safeguard cell function, and accelerate commercialization.
Our customers include cell and gene therapy developers, academic institutions, contract development and manufacturing organizations (CDMOs), and biopharma companies.
You can access our SEC filings, annual reports, quarterly results, and earnings presentations directly on our Investor Relations site.
BioLife Solutions does not pay dividends. The company intends to retain earnings to fund continued growth and expansion.
Information about our executive leadership, advisory boards, and Board of Directors is available on the Leadership page of our website.
BioLife Solutions’ independent registered public accounting firm is BDO USA, LLP.
Our transfer agent is Broadridge Corporate Issuer Solutions, Inc. Shareholders may contact Broadridge for assistance with changes of address, stock transfer, lost certificates, or account consolidation. Broadridge Corporate Issuer Solutions, Inc. | P.O. Box 1342, Brentwood, New York 11717 | (877) 830 - 4936 | shareholder@broadridge.com
For investor inquiries, please contact either Troy Wichterman, Chief Financial Officer (425) 402-1400 twichterman@biolifesolutions.com or Alliance Advisors IR Jody Cain (310) 691-7100 jcain@allianceadvisors.com
We believe the promise of cell and gene therapies starts with the integrity of a single cell
Advancing the future of cell and gene therapy
The human body can heal itself. Cell and gene therapies are designed to augment the patient’s ability to fight disease but only if the living cells behind those therapies remain viable and functional throughout the production processes. At BioLife Solutions, our mission is to protect the integrity of cells and provide trusted tools, services, and expertise that can enable our customers to advance the development and delivery of cell and gene therapies. We believe the future of cell and gene therapies hinges on the integrity of every single cell and we are here to protect that promise.
We understand the technical demands of bioprocessing in this field, and our advanced biopreservation expertise, cell culture optimization products, innovative storage systems, and closed-system manufacturing solutions are designed to enhance process efficiency, maintain cellular viability, and ensure reproducibility at every stage. Whether scaling up from R&D, navigating clinical trials or optimizing cryopreservation protocols for commercial production, we provide the tools and experience to streamline your workflow and safeguard your therapies.
Streamline workflows and safeguard therapies
GMP-COMPATIBLE
Precision
biopreservation
for
maximum
viability
GMP-COMPATIBLE
Our biopreservation media and storage solutions are engineered to maintain cell integrity and functionality. With GMP-compatible, validated formulations, we help you reduce variability and improve post-thaw recovery, ensuring robust and reproducible outcomes.
CELL VIABILITY
Best
practices
in
cell
processing
CELL VIABILITY
With deep industry experience, regulatory support, and a commitment to innovation, BioLife Solutions is dedicated to supporting bioprocess engineers in overcoming complex manufacturing challenges. Whether optimizing cryopreservation protocols or ensuring the seamless transition from lab to clinic, we are dedicated to your success.
QUALITY & COMPLIANCE
Scalable
manufacturing
and
process
optimization
QUALITY & COMPLIANCE
Enhance efficiency and consistency in your cell processing workflow with our closed-system tools for fluid management and cell processing that are automation ready. Reduce manual handling errors, improve throughput, and achieve higher standards of quality and compliance as you scale towards commercialization.
REGULATORY SUPPORT
Your
partner
in
bioprocess
optimization
REGULATORY SUPPORT
BioLife Solutions delivers specialized tools and expertise to help bioprocess engineers streamline and strengthen biopreservation processes across the cell therapy workflow. From selecting the right biopreservation media to minimizing cell loss during freezing, storage, and transports, our solutions are designed to improve consistency, reduce risk, and support a successful transition from development to clinical application.
Work with experts who understand your biopreservation challenges
Connect with
our
experts
Explore
our
solutions
Collaborative and comprehensive CDMO support
At BioLife Solutions, we partner with leading contract development and manufacturing organizations (CDMOs) to enhance their biopreservation and cell processing capabilities. By providing advanced tools, regulatory support, and process optimization strategies, we empower CDMOs to better serve therapy developers, ensuring quality, consistency, and scalability in cell therapy manufacturing.
Regulatory
readiness
Navigating the complex regulatory landscape of cell and gene therapy requires a proactive approach. BioLife Solutions offers experienced regulatory support to help prepare your biopreservation and cell processing methods to meet global standards. From IND and BLA submissions to compliance with GMP, FDA, and EMA guidelines, our solutions help streamline approval pathways.
STORE
CellSeal®
CryoCase
Alleviate CGT container challenges like fracture risk, bag burping or high rates of particulates
Data-driven
decision making
Stay ahead with our comprehensive Evidence Library, a curated collection of scientific publications, white papers, and case studies demonstrating the efficacy of BioLife Solutions’ technologies. Access peer-reviewed research, real-world application data, and expert insights to support your bioprocessing and regulatory strategies.
